Psychedelics offer promising potential as treatments for mental health conditions. However, research on psychedelics has often failed to consider biological sex differences. This panel will explore how women’s reproductive biology may impact psychedelic safety and efficacy. Presenters will review existing evidence on sex differences and make recommendations to improve psychedelic research, access, and outcomes for women. By considering women’s physiology, we can work towards more informed, equitable, and effective psychedelic therapies.